Cargando…

Cancer cell proliferation is inhibited by specific modulation frequencies

BACKGROUND: There is clinical evidence that very low and safe levels of amplitude-modulated electromagnetic fields administered via an intrabuccal spoon-shaped probe may elicit therapeutic responses in patients with cancer. However, there is no known mechanism explaining the anti-proliferative effec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zimmerman, J W, Pennison, M J, Brezovich, I, Yi, N, Yang, C T, Ramaker, R, Absher, D, Myers, R M, Kuster, N, Costa, F P, Barbault, A, Pasche, B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3261663/ https://www.ncbi.nlm.nih.gov/pubmed/22134506 http://dx.doi.org/10.1038/bjc.2011.523

Ejemplares similares

Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields
por: Costa, F P, et al.
Publicado: (2011)

Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies
por: Zimmerman, Jacquelyn W., et al.
Publicado: (2013)

Amplitude-modulated electromagnetic fields for the treatment of cancer: Discovery of tumor-specific frequencies and assessment of a novel therapeutic approach
por: Barbault, Alexandre, et al.
Publicado: (2009)

TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy
por: Pirovano, Giacomo, et al.
Publicado: (2017)

Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines
por: Uziel, O, et al.
Publicado: (2005)

Sulphoxythiocarbamates modify cysteine residues in HSP90 causing degradation of client proteins and inhibition of cancer cell proliferation
por: Zhang, Y, et al.
Publicado: (2014)

Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development
por: Camidge, D R, et al.
Publicado: (2005)

The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation
por: Isham, C R, et al.
Publicado: (2012)

Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion
por: Ma, P C, et al.
Publicado: (2007)

Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation
por: Cheng, G, et al.
Publicado: (2014)

Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo
por: Ewald, J A, et al.
Publicado: (2008)

BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation
por: Hennig, R, et al.
Publicado: (2008)

Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines
por: Barabutis, N, et al.
Publicado: (2008)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation
por: Noble, Amanda R, et al.
Publicado: (2018)

Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism
por: Cambien, B, et al.
Publicado: (2009)

Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma
por: Fujiwara-Okada, Y, et al.
Publicado: (2013)

γ-Tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways
por: Yap, W N, et al.
Publicado: (2008)

Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer
por: White, N M A, et al.
Publicado: (2010)

Prostate cancer cell malignancy via modulation of HIF-1α pathway with isoflurane and propofol alone and in combination
por: Huang, H, et al.
Publicado: (2014)

D-Glucuronyl C5-epimerase suppresses small-cell lung cancer cell proliferation in vitro and tumour growth in vivo
por: Grigorieva, E V, et al.
Publicado: (2011)

FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer
por: Marzi, L, et al.
Publicado: (2016)

Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients
por: Gabasa, M, et al.
Publicado: (2017)

Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents
por: He, G, et al.
Publicado: (2013)

hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines
por: Masi, A, et al.
Publicado: (2005)

Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo
por: Hristodorov, D, et al.
Publicado: (2013)

Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity
por: den Brok, M H M G M, et al.
Publicado: (2006)

Oxidative stress specifically downregulates survivin to promote breast tumour formation
por: Pervin, S, et al.
Publicado: (2013)

Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation
por: Minas, V, et al.
Publicado: (2007)

Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential
por: Khan, S, et al.
Publicado: (2009)

E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines
por: Lombaerts, M, et al.
Publicado: (2006)

Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
por: Barros-Silva, J D, et al.
Publicado: (2009)

Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100
por: Smith, N F, et al.
Publicado: (2008)

In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells
por: Jiang, P, et al.
Publicado: (2014)

Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells
por: Johnson, N, et al.
Publicado: (2010)

Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells
por: Thiel, U, et al.
Publicado: (2011)

Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells
por: Jeon, T-Y, et al.
Publicado: (2010)

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
por: Michlmayr, A, et al.
Publicado: (2010)

Aurora B expression modulates paclitaxel response in non-small cell lung cancer
por: Al-Khafaji, Ahmed SK, et al.
Publicado: (2017)

TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells
por: Cantarella, G, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_opa38rhfnfn6gpujmh2ldb2mql